A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial | Zendy

Wadim M. I. de Boon | Zendy; Michiel J. van Esdonk | Zendy; Frederik E. Stuurman | Zendy; Nienke R. Biermasz | Zendy; Laurent Pons | Zendy; Isabelle Paty | Zendy; Jacobus Burggraaf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial

Author(s) -

Wadim M. I. de Boon,

Michiel J. van Esdonk,

Frederik E. Stuurman,

Nienke R. Biermasz,

Laurent Pons,

Isabelle Paty,

Jacobus Burggraaf

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-01364

Subject(s) - somatostatin , endocrinology , medicine , tolerability , orthostatic vital signs , prolactin , dopamine agonist , placebo , dopamine , pharmacokinetics , hormone , adverse effect , blood pressure , dopaminergic , alternative medicine , pathology

A somatostatin-dopamine chimera (BIM23B065) was under investigation to reduce GH secretion for the treatment of pituitary adenomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research